NUP210L

Across TCGA pan-cancer cohorts, NUP210L Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NUP210L data layer compared with 18 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher NUP210L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NUP210L expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

ESCA, UCEC, and LIHC are the cancer types where NUP210L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	IV	0.095	0.512	.008	30	view →
UCEC	OS	Median	II,III,IV	0.897	0.453	.017	28	view →
LIHC	OS	Median	All	0.296	0.789	<.001	24	view →
KIRC	DFS	Median	IV	0.085	0.620	<.001	12	view →
PRAD	DFS	Median	All	0.486	0.936	<.001	6	view →
LUAD	OS	Median	III,IV	0.163	0.659	.035	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
LUSC	DFS	Median	All	0.923	0.749	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NUP210L–ESCA (OS)

Open the ESCA breakdown →